Breast Cancer Treatment Protocols Flashcards

1
Q

Localized disease - What stage?

A

0, I, II, IIIA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

In the USA and other developed nations where screening is performed, most patients present with …?

A

Localized BC that is detected by a screening mammogram.

Less commonly, pts present with a palpable mass that is either self-detected or detected by a health care provider.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Stage 0 - LCIS - Management includes:

A
  1. Surveillance alone (ie, mammography).
  2. Surveillance plus raloxifene (for postmenopausal women).
  3. Tamoxifen (for women of any menopausal status).
  4. Bil proph mastectomy (usually in patients who are very concerned about breast cancer risk and have either a strong family history of mammographically dense breasts that impair surveillance).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

If LCIS is detected on stereotactic biopsy …?

A

WIDE EXCISION IS INDICATED.

==> In 10-20% of cases, this may reveal INV CA or DCIS that requires additional local or systemic Tx.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

LCIS - Surgical excision?

A

Surgical excision to NEGATIVE MARGINS is NOT indicated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

LCIS is a/w about a …?

A

5% 5y risk.

+ 20-30% lifetime risk of developing inv BC.

==> which may be ipsilateral/contralateral and may be ductal/lobular in origin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

PLEOMORPHIC LCIS:

A

Is a LCIS variant that warrants special consideration.

***Tx should include excision to NEGATIVE MARGINS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Stage 0 - DCIS - Primary Tx options include:

A
  1. Lumpectomy without axillary assessment, + whole-breast RT.
    * Use of radiation boost (photons, brachytherapy, or electron beam) to the tumor bed is recommended, especially in pts age >50y.
  2. Total mastectomy +/- SNLB +/- Breast reconstruction.
  3. Lumpectomy without LN surgery and without RT (lower-level evidence).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Stage 0 - DCIS - Considerations include the following:

A
  1. Although ALND or SLNB is often NOT performed, SLNB may be done in some cases IF an initial core biopsy showed DCIS, because more extensive sampling may show invasive carcinoma.
  2. In the absence of risk factors for recurrence (eg palpable mass, larger size, higher grade, close or involved margins, age <50y), SOME pts may NOT receive RT.
  3. Consider risk-reduction therapy with tamoxifen for 5y for pts treated with lumpectomy and RT, especially those with ER(+) DCIS.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Stage I, IIA, IIB, or IIIA (T3N1M0) - Tx for these stages of BC include the following:

A
  1. Sx.
  2. RT in most cases.
  3. Adjuvant chemo, endocrine therapy, or biologic therapy in some cases.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Stage I, IIA, IIB, or IIIA (T3N1M0) - Sx options include:

A
  1. Lumpectomy to (-)margins + RT.
  2. Mastectomy.
  3. Mastectomy with reconstruction.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Axillary assessment is usually performed with …?

A

SLNB.

ALND may be considered in cases of (+)node BC.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Stage I, IIA, IIB, IIIA (T3N1M0) - RT is used in …?

A

Pts who undergo lumpectomy or, in selected cases, after mastectomy;

==> Tx fields are determined by axillary node status.

**RT should FOLLOW chemo, if chemo is indicated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pts undergoing lumpectomy with surgical axillary staging - RT recommendations are based on the pts axillary node status, as follows:

A

4 or more nodes ==> Whole-breast RT +/- boost to the tumor bed +/- to the infraclavicular and supraclavicular areas should also be considered.

1-3 nodes ==> Whole-breast RT +/- boost to the tumor bed +/- to the infraclavicular and supraclavicular areas should be considered + as should RT to internal mammary nodes.

(-)Nodes ==> Whole-breast RT +/- boost to the tumor bed.
*partial breast irradiation (PBI) may be considered in selected pts.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pts undergoing total mastectomy with surgical axillary staging, +/- reconstruction - RT recommendations are based on the pts axillary node status, as follows:

A

4 or more nodes ==> Post-chemo RT to the chest wall + the infra/supraclavicular areas. Consider RT to internal mammary nodes.

1-3 nodes ==> Consider post-chemo RT to the chest wall +/- the infra/supraclavicular areas. Consider RT to internal mammary nodes.

Negative nodes, tumor <5cm, margins <1mm ==> Post-chemo RT to the chest wall is recommended.

Negative nodes, tumor <5cm, margins >1mm ==> NO RT IS NEEDED (!).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pts with large, clinical stage IIA, IIB, IIIA (T3N1M0) tumors:

A

PRE-op chemo should be considered in these pts if they have any of the following:

  1. T3-T4.
  2. (+)Nodes.
  3. ER(-).
  4. HER2(+).
  5. Tumors that need downsizing for Sx.

***If the pt has clinically (-)nodes, consider SLNB.

***If the pt has clinically (+)nodes, consider a core Bx or FNA, then SLNB if FNA or core Bx is negative.

17
Q

Chemo regimens are as follows:

A

TAC ==> Docetaxel (Taxotere) + Doxo + Cyclophos /3wk for 6 cycles.

Dose-dense ACP ==> Doxo + Cyclo /2wk for 4 cycles. Followed by PACLITAXEL with CSF support.

AC ==> Doxo + Cyclo /3wk for 4 cycles (comparable to CMF).

TC ==> Docetaxel + Cyclo /3wk for 4 cycles.

18
Q

For HER2(+) tumors, the following NEOadjuvant regimen is administered every 3wk for 3-6 cycles:

A

Pertuzumab (Perjeta) + Trastuzumab + Docetaxel

19
Q

Adjuvant chemotherapy - HER2(+) localized disease - Stage I, IIA, IIB, IIIA (T3N1M0):

A

Anti-HER2 directed therapy is indicated for use + CHEMO in pts with HER2(+) disease.

20
Q

Tx considerations regarding trastuzumab:

A
  1. CURRENTLY, the ONLY anti-HER2 shown to REDUCE RECURRENCE.
  2. In studies of trastuzumab, pts were randomly assigned to receive chemo alone or + trastuzumab.
  3. Overlapping trastuzumab Tx with TAXANE Tx ==> Suggested to be more effective than a strategy of completing all chemo first AND THEN administering trastuzumab.
  4. Trastuzumab cannot be given CONCURRENTLY with anthracyclines, because of the high risk of cardiotoxicity.
21
Q

Adjuvant chemotherapy - HER2(+) localized disease - Stage I, IIA, IIB, IIIA (T3N1M0) - NON-trastuzumab regimens:

A

TAC ==> Docetaxel + Doxo + Cyclo /3wk for 6cycles.

Dose-dense ACP ==> Doxo + Cyclo /2wk for 4cycles ==> Followed by PACLITAXEL /2wk + CSF support.

AC ==> Doxo + Cyclo /3wk for 4 cycles (comparable to CMF).

TC ==> Docetaxel + Cyclo /3wk for 4 cycles.

22
Q

Adjuvant chemotherapy - HER2(+) localized disease - Stage I, IIA, IIB, IIIA (T3N1M0) - Trastuzumab-containing regimens:

A
  1. AC-PACLITAXEL-TRASTUZUMAB:

==> Doxo + Cyclo /3wk ==> Followed by paclitaxel /wk for 12 cycles OR /3wk for 4 cycles CONCURRENTLY with trastuzumab ==> Followed by trastuzumab /3wk for 14 doses, for 1y.

  1. AC-DOCETAXEL-TRASTUZUMAB:

Doxo + Cyclo /3wk for 4 cycles ==> Followed by docetaxel /3wk for 4 cycles given CONCURRENTLY with trastuzumab for 12wks ==> Followed by trastuzumab /3wk to complete the 1y.

  1. TCH:

Docetaxel + Carboplatin /3wk for 6 cycles + trastuzumab weekly for 18wks ==> Followed by trastuzumab /3wk to complete 1y.

**this regimen is more appropriate for pts with contra to anthracyclines.

23
Q

Adjuvant chemo, HER2(-), Localized Disease - Stage I, IIA, IIB, or IIIA (T3N1M0) - FIRST-gen regimen role:

A

Considered LESS effective than 2nd, 3rd-gen regimens - Do play a role in selected situations.

CMF ==> Pts with contra to anthracycline (cardiac disease) and/or taxane Tx.

AC ==> Pts with contra to taxane Tx (neuropathy).

24
Q

Adjuvant chemo, HER2(-), Localized Disease - Stage I, IIA, IIB, or IIIA (T3N1M0) - 1st gen regimens:

A

CMF ==> Cyclo + MTX + 5FU 6 cycles.

AC ==> Doxo + Cyclo 4 cycles.

CMF (PO) ==> Cyclo + MTX + 5-FU 6 cycles.

CMF (IV) ==> Cyclo + MTX + 5FU 8 cycles.

25
Q

Adjuvant chemo, HER2(-), Localized Disease - Stage I, IIA, IIB, or IIIA (T3N1M0) - 2nd gen regimens importance:

A

More effective than other regimens (eg CMF).

==> Some of them appropriate for pts who desire LESS PROLONGED REGIMENS.

==> Geographic variation in the use of these regimens:

DC and AC-P are more commonly used in the USA, and epirubicin-containing regimens are more commonly used in Europe.

26
Q

Adjuvant chemo, HER2(-), Localized Disease - Stage I, IIA, IIB, or IIIA (T3N1M0) - 2nd gen regimens:

A

FAC ==> 5FU + Doxo + Cyclo 6 cycles. (More effective than CMF)

CEF ==> Cyclo + Epirubicin + 5FU 6 cycles (more toxic than other alternatives in this category; with cotrimoxazole support).

Dose-dense AC-P ==> Doxo + Cyclo 4 cycles ==> Followed by paclitaxel 4 cycles with CSF support.

TC ==> Docetaxel + Cyclo 4 cycles (more effective than AC).

27
Q

Adjuvant chemo, HER2(-), Localized Disease - Stage I, IIA, IIB, or IIIA (T3N1M0) - 3rd gen regimens importance:

A

More effective than some 2nd gen. Include both taxanes and anthracyclines.

28
Q

Adjuvant chemo, HER2(-), Localized Disease - Stage I, IIA, IIB, or IIIA (T3N1M0) - 3rd gen regimens:

A

AC-P ==> Doxo + Cyclo ==> Followed by paclitaxel.

TAC ==> Docetaxel + Doxo + Cyclo (more effective than FAC; CSF support recommended).

FEC-docetaxel ==> 5FU + Epirubicin + Cyclophosphamide ==> Followed by docetaxel (more effective than 6 cycles of FEC).

FEC-paclitaxel ==> 5FU + Epirubicin + Cyclo ==> Followed by paclitaxel.